Corcept Therapeutics | CORT - Interest Expense On Debt


Corcept Therapeutics reported $823.61M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alaunos Therapeutics USD 0 0 Dec/2023
ANI Pharmaceuticals USD 4.73M 711K Sep/2025
Ardelyx USD 5.8M 784K Sep/2025
Assertio Holdings USD 758K 1000 Jun/2024
Aurora Cannabis CAD 2.22M 442K Sep/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Canopy Growth CAD 8.8M 938K Sep/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
J&J USD 18M 290M Sep/2025
Knight Therapeutics CAD 2.37M 6K Sep/2025
Lexicon Pharmaceuticals USD 2.21M 2.74M Jun/2024
Merck USD 412M 85M Dec/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Novartis USD 281M 8M Sep/2025
Novartis USD 281M 8M Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 4.28M 456K Sep/2025
Pfizer USD 711M 59M Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
TG Therapeutics USD 6.72M 4K Sep/2025